Mona Mashayekhi is an Endocrinology/Metabolic physician affiliated with Vanderbilt University. OpenAlex indexes 96 publications with 4,064 citations (h-index 22); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
Sponsor: Vanderbilt University Medical Center
- SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot
Sponsor: Vanderbilt University Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
100%GLP-1 receptor agonist64.3%Ozempic100%Part D<11 patientsBiguanide (metformin)18.6%Metformin Hcl100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2023–2026 per NIH RePORTER. The latest:
- The Effect of SGLT2 Inhibition on Adipose Tissue Inflammation and Endothelial Function
Vanderbilt University Medical Center
FY2026$185,436K23HL159351 - The Effect of SGLT2 Inhibition on Adipose Tissue Inflammation and Endothelial Function
Vanderbilt University Medical Center
FY2025$185,436K23HL159351 - The Effect of SGLT2 Inhibition on Adipose Tissue Inflammation and Endothelial Function
Vanderbilt University Medical Center
FY2024$185,436K23HL159351
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- RISING STARS: Effects of a GLP-1 receptor polymorphism on responses to liraglutide
Journal of Endocrinology
2025 - CD3+ T-cell: CD14+ monocyte complexes are dynamic and increased with HIV and glucose intolerance
The Journal of Immunology
2025 - Mapping CMV-related immune signatures in blood, aorta and perivascular mediastinal adipose tissue
Philosophical Transactions of the Royal Society B Biological Sciences
2025 - Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors
Trends in Endocrinology and Metabolism
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Ingrid Mayer, MD
Vanderbilt University
Michael Debaun, MD
Vanderbilt University
Olalekan Oluwole, MD, MPH
Vanderbilt University
Volker Haase, MD
Vanderbilt University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”